Higher risk for cardiovascular mortality, kidney disease progression seen with serum 25(OH)D\u2009<10 ng\/mL<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, May 17, 2024 (HealthDay News) — Vitamin D deficiency is associated with increased risks for cardiovascular mortality and chronic kidney disease (CKD) progression in patients with early-stage disease, according to a study published online May 11 in\u00a0the Journal of Endocrinological Investigation<\/em>.<\/p>\n Yanhong Lin, from Southern Medical University in Guangzhou, China, and colleagues examined the effects of 25-hydroxyvitamin D (25[OH]D) deficiency on cardiovascular mortality and kidney outcomes in patients with early-stage CKD. The analysis included 9,229 adult patients with CKD (stages 1 to 3) from 19 medical centers across China (January 2000 to May 2021).<\/p>\n The researchers found that compared with patients having 25(OH)D\u00e2\u0080\u0089\u00e2\u0089\u00a520 ng\/mL, a there was a significantly higher risk for cardiovascular mortality (hazard ratio, 1.90) and CKD progression (hazard ratio, 2.20) as well as a steeper annual decline in estimated glomerular filtration rate (estimate, \u00e2\u0088\u00927.87 percent per year) in those with serum 25(OH)D\u00e2\u0080\u0089<10 ng\/mL.<\/p>\n “In conclusion, 25(OH)D deficiency was common in patients with early-stage CKD,” the authors write. “Vitamin D status should be closely monitored in patients with early CKD. Well-designed randomized clinical trials are needed to determine whether timely vitamin D supplementation can prevent cardiovascular events and loss of kidney function in patients with early-stage CKD and 25(OH)D deficiency.”<\/p>\n Abstract\/Full Text\u00a0(subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n